Gefitinib, another EGFR inhibitor used to treat lung cancers 16, or cetuximab, a monoclonal antibody against EGFR, reduced the production of VEGF and CXCL8 in different cancer cells, which may explain their therapeutic efficacy 17, 18. Here, CXCL8 is linked to lung cancer.